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Abstract
IL-17 is believed to be important for protection against extracellular pathogens, where clearance is dependent on
neutrophil recruitment and local activation of epithelial cell defences. However, the role of IL-17 in protection against
intracellular pathogens such as Chlamydia is less clear. We have compared (i) the course of natural genital tract C.
muridarum infection, (ii) the development of oviduct pathology and (iii) the development of vaccine-induced immunity
against infection in wild type (WT) BALB/c and IL-17 knockout mice (IL-17-/-) to determine if IL-17-mediated immunity
is implicated in the development of infection-induced pathology and/or protection. Both the magnitude and duration of
genital infection was significantly reduced in IL-17-/- mice compared to BALB/c. Similarly, hydrosalpinx was also
greatly reduced in IL-17-/- mice and this correlated with reduced neutrophil and macrophage infiltration of oviduct
tissues. Matrix metalloproteinase (MMP) 9 and MMP2 were increased in WT oviducts compared to IL-17-/- animals at
day 7 post-infection. In contrast, oviducts from IL-17-/- mice contained higher MMP9 and MMP2 at day 21. Infection
also elicited higher levels of Chlamydia-neutralizing antibody in serum of IL-17-/- mice than WT mice. Following
intranasal immunization with C. muridarum Major Outer Membrane Protein (MOMP) and cholera toxin plus CpG
adjuvants, significantly higher levels of chlamydial MOMP-specific IgG and IgA were found in serum and vaginal
washes of IL-17-/- mice. T cell proliferation and IFNγ production by splenocytes was greater in WT animals following
in vitro re-stimulation, however vaccination was only effective at reducing infection in WT, not IL-17-/- mice.
Intranasal or transcutaneous immunization protected WT but not IL-17-/- mice against hydrosalpinx development.
Our data show that in the absence of IL-17, the severity of C. muridarum genital infection and associated oviduct
pathology are significantly attenuated, however neither infection or pathology can be reduced further by vaccination
protocols that effectively protect WT mice.
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Introduction
The obligate, intracellular human pathogen Chlamydia
trachomatis is the most common bacterial sexually transmitted
disease worldwide and the cause of preventable blindness
(trachoma) in developing countries (WHO 2007). More than
100 million new infections occur annually with untreated genital
infection causing pelvic inflammatory disease (PID) in women
and prostatitis in men, leading to infertility in both sexes.
Currently the cost of treating pelvic inflammatory disease (PID)
alone in the United States is in excess of US$4 billion annually
(WHO 2012). To study the mechanisms underlying immune
protection against infection as well as the infection induced
inflammation that results in oviduct occlusion, the mouse model
of genital C. muridarum infection is commonly used as it
closely replicates many facets of human C. trachomatis
infection [1] [2] [3]. Mouse studies have shown that CD4+ T-
helper1 (Th1) cells and interferon gamma (IFNγ) dependent
immunity is essential for resolution of a primary genital tract
infection [2], whilst antibodies and CD8+ T cell-mediated
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e76664
immunity contribute to the host’s resistance to chlamydial
reinfection [4] [5] [6].
The classical Th1 and Th2 paradigm, described by Mosman
and Coffman [7] has underpinned much immunological
research for the past 20 years and has recently been extended
to include a number of other CD4 subsets defined by cytokine
secretion patterns (reviewed in 8). One of the newly described
T helper cell populations Th17 cells are characterized by the
secretion of the cytokine interleukin 17 (IL-17) [9] [10] and have
been implicated in inflammation [11], autoimmunity [12] and
protection against various fungal [13] [14] and viral [15]
pathogens. Importantly, IL-17 has also been shown to be
important in protection against a number of bacterial pathogens
including the extracellular bacterium Klebsiella pneumoniae
[16] and intracellular bacteria including Mycobacterium
tuberculosis, Mycoplasma pneumoniae and Listeria
monocytogenes [17] [18] [19]. As Chlamydia has a bi-phasic
developmental cycle, with both an extracellular and intracellular
stage, and because the cytokine milieu necessary to activate
Th17 cells in humans and mice is produced in response to a
chlamydial genital infection [20], the role of Th17 cells during
chlamydial infection is of interest. Subsequent to Th17 cell
activation, an increase in IL-17 production at the early stages of
infection may benefit the infected host by (i) inducing
chemokines (IL8/CXCL8) that recruit neutrophils and (ii)
promoting IL-22 mediated production of defensins at the site of
infection [21,22]. In contrast, IL-17 may play a role in
stimulating the production of the neutrophil enzyme matrix
metalloproteinase-9 (MMP-9), which in turn increases
neutrophil infiltrates in the upper genital tract and stimulates
adverse hydrosalpinx formation via enzymatic modification of
chemokines and production of chemotactic collagen peptides
[23] [24]. Indeed, IL-17-mediated activation of MMPs has been
demonstrated to play a role in a number of inflammatory
conditions including inflammation of mouse airways [25],
cartilage destruction in mouse models of arthritis [26,27],
hepatocellular carcinoma metastasis [28] and inflammation
associated with human atherosclerosis [29], a condition that
has been linked to C. pneumoniae infection [30].
We, and others have shown that immunization of mice via
the intranasal (IN) route is an effective means of eliciting
protective immunity against genital C. muridarum infection [31]
[32] [33,34]. Interestingly, recent studies by Zygmunt et al. [35]
have shown that the IN route of immunization preferentially
induces a Th17 response, further suggesting that IL-17 may
have a role in genital tract chlamydial immunity. Lu et al. [36]
however, showed that the protection against genital infection
afforded by IN immunization with live Chlamydia correlated with
a T cell response characterised by high IFNγ and low IL-17
production. Furthermore, Yu et al. [37] immunized mice by the
subcutaneous route and found that protection against genital
C. muridarum infection was conferred by multifunctional T cells,
secreting either IFNγ and TNFα or IFNγ and IL-17. Thus the
data on the role of Th17 cells/IL-17 in protection against genital
chlamydial infection is not fully understood.
C. muridarum lung infection has been shown to stimulate
early IL-17 production after intranasal delivery of the bacterium.
Neutralising the initial IL-17 response enhanced Chlamydia
replication and decreased mouse survival [38], suggesting that
IL-17 plays a protective role during a chlamydial lung infection.
Interestingly, a prior C. muridarum respiratory infection also
protects against a subsequent genital infection [39]. In contrast
to respiratory tract infection, IL-17 receptor-deficient mice given
a primary C. muridarum genital tract infection resolved the
infection normally in the absence of IL-17 signalling [22]. These
conflicting data emphasize that the role of IL-17 in the natural
clearance of a chlamydial genital infection, the development of
inflammation following infection and in vaccine-induced
protective immunity may be multi-faceted and remain to be fully
elucidated.
In this study, we have infected IL-17-/- and wild type (WT)
mice with C. muridarum and monitored the clearance of
infection, the development of inflammatory pathology
(hydrosalpinx) and vaccine-induced protection against both
bacterial burden and pathology following IN and
transcutaneous immunization (TCI) to determine the
requirement for IL-17 during each of these phases of infection.
We found that both the magnitude and duration of C.
muridarum genital infection and the development of
hydrosalpinx were reduced in IL-17-/- mice compared to WT
BALB/c mice. This correlated with significantly decreased
recruitment of both neutrophils and macrophages into the
oviducts of IL-17-/- mice, decreased matrix metalloproteinase
activity and increased serum levels of Chlamydia-neutralizing
antibody. Furthermore, immunization by either the IN [40] or
TCI [41] routes reduced both infection and hydrosalpinx in WT
mice, which exhibited higher T cell proliferation and IFNγ
production following IN immunization, but provided no extra
protection against either infection or pathology in IL-17-
deficient mice.
Materials and Methods
Ethics statement
All procedures were approved by the Queensland University
of Technology Animal Research Ethics Committee (Approval
0700000346) and carried out in strict accordance with any
recommendations. All efforts were made to minimize suffering.
Chlamydia stocks, animals and infection
Chlamydia muridarum (Weiss: ATCC VR-123, Virginia, USA)
was propagated in McCoy cells and purified using a
discontinuous Renografin gradient (Bayer Ltd, Pymble NSW,
Australia) to yield purified elementary bodies, which were
aliquoted in sucrose-phosphate-glutamate (SPG) and stored at
-80 °C. Female BALB/c WT (Animal Resource Centre, Perth,
Australia) or IL-17 deficient mice bred on a BALB/c background
[42] were used at 6-8 weeks of age. Mice were given 2.5 mg of
medroxyprogesterone acetate (Depo-Provera, Pfizer, NSW,
Australia) subcutaneously to synchronise the estrous cycle and
increase their susceptibility to a chlamydial infection. Seven
days later, mice received an intravaginal inoculation of 5x104
inclusion forming units (IFUs) of live C. muridarum. Non-
infected controls received SPG only. The experiment was
repeated three times, with six mice per experimental group and
three mice per control group.
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Monitoring of live Chlamydia shedding from vaginal
swabs
In order to characterise the course of the chlamydial infection
in WT and IL-17 -/- mice, vaginal swabs (Copan, Murrieta, CA)
were taken every 3 days for 21 days. Following collection, each
swab was immersed in 500 µl of SPG buffer in a microfuge
tube with 3 sterile glass beads. The swab was vortexed and
stored at -80 °C. After all samples were collected, the tubes
were quickly thawed and again vortexed to release the
organisms from the swab. McCoy cell monolayers grown on 48
well plates were inoculated with 10 µL of specimen from swabs
collected on days 3 to 9, and 25 µL from specimens collected
on days 12 to 21. After 4 h incubation at 37 °C, the inoculum
was removed and replaced with fresh media containing 1
µg/mL of cycloheximide. The plate was incubated for a further
24 h then fixed with methanol. The inclusions were visualised
by staining with rabbit anti-C. trachomatis antibody (Pierce/
Progen, Richards, Australia) and the Immunopure ABC/DAB
staining kit (Pierce/Progen, Richards, Australia). Ten random
fields of view per well were counted per swab sample. The total
number of IFU was calculated by averaging the number of
counts per field and multiplying by the number of IFU per well
and the dilution factor.
Evaluating chronic pathology
Mice were sacrificed 35 days following the primary infection
and the female reproductive tissues were removed. At the
macroscopic level, upper genital tract pathology was assessed
by measuring the size of hydrosalpinx as previously described
[43,44].
Staining of oviducts and uterine horns for neutrophils
and macrophages
Female BALB/c WT (n=3) and IL-17 -/- mice (n=3) were
progesterone treated and infected with C. muridarum as
described above. The animals were euthanized on day 6 and
oviducts and uterine horns were collected from each animal.
Tissues were fixed in 10% neutral buffered formalin overnight.
Immunohistochemistry was performed at the Queensland
Institute of Medical Research (QIMR). Samples were paraffin
embedded and sections were cut and affixed to adhesive
slides, then subjected to antigen retrieval and blocking. For
neutrophil detection, primary antibody rat anti-mouse neutrophil
Gr-1 (NIMP-R14; Abcam, Sapphire Bioscience, NSW,
Australia) was added, followed by Rat Probe (Biocare Medical,
CA, USA) and Rat-on-Mouse HRP-Polymer (Biocare Medical),
and then developed with Betazoid DAB (Biocare Medical). For
macrophage detection, primary antibody rat anti-mouse F4/80
(CI:A3-1; Abcam) was added, followed by alkaline phosphatase
conjugated goat anti-rat Ig (Chemicon, CA, USA), then
developed with Vulcan Fast Red Chromogen (Biocare
Medical). Slides were counterstained in Mayer’s haematoxylin,
scanned at QIMR using Aperio Scanscope XT and analyzed
using Aperio ImageScope software v12. Staining intensity was
quantified by measuring strong positive pixels using
preconfigured positive pixel count v9 algorithm and expressing
as a percentage of total pixels per tissue.
Evaluation of metalloproteinase activity
Cervix, uterine horn and oviduct tissues were collected on
days 7, 14 and 21 post-infection (p.i.) into 500 µL of phosphate
buffer saline (PBS) and stored at -80 °C. For assay of
metalloproteinase activity, the tissues were homogenized and
processed for gelatin zymography, as described previously
[45]. In addition, tissue homogenates were used for the antigen
capture enzyme-linked immunoassay detection of total MMP-2
and proMMP-9, according to the manufacturers instructions
(R&D Systems, Inc., Minneapolis, MN). Gelatin zymography
provides relative assessment of gelatinase activity while ELISA
provides assessment of zymogen MMP-9 present in the
targeted tissue.
Antigen and adjuvants
Major Outer Membrane Protein (MOMP, MBP-tagged) was
prepared, as previously described [41], from transformed
Escherichia coli (DH5α [pMMM3]) containing the recombinant
MBP-MOMP encoding pMAL-c2 vector. Synthetic CpG-1826
oligonucleotides, with a phosphorothioate backbone (5’-
TCCATGACGTTCCTGACGTT- 3’, Sigma-Aldrich, Castle Hill,
NSW, Australia), and cholera toxin (CT, Sapphire Bioscience,
Waterloo, NSW, Australia) adjuvants, were prepared in sterile
PBS.
Intranasal (IN) Immunization
Mice (n=5 per group) were lightly sedated with 2-4%
Isoflurane in 4 L/min oxygen. Vaccine containing 100 µg MBP-
MOMP, 5 µg CpG-1826 and 2.5 µg CT was delivered
intranasally in a 10 µL volume via micropipette, with each nare
receiving 5 µL. Immunizations were administered 3 times at
weekly intervals, and an immunization booster was given 2
weeks following the third immunization.
Transcutaneous immunization
Mice (n=5 per group) were anaesthetised intraperitoneally
with xylazine (90 mg/kg) and ketamine (10 mg/kg). A small
area (≈1 cm2) of the lumbar region was shaved and swabbed
with acetone. The area was then swabbed with a skin
permeabilising solution containing PBS and 100% ethanol in
equal volumes, with 0.33% w/v 1-Dodecylpyridinium chloride
(DPC), 0.33% w/v Isopropyl myristate (IPM) and 0.33% w/v N-
methylpyrrolidone (NMP). Chemical residue was removed by
swabbing the exposed skin with sterile PBS. Before
administering vaccine, 12.5 ng of recombinant-mouse GM-CSF
(Invitrogen, Mount Waverley, VIC, Australia) was added to the
shaved region. Vaccine containing 100 µg MBP-MOMP, 5 µg
CpG-1826 and 2.5 µg CT was then delivered in a 50 µL volume
to the immunization site and allowed to absorb into the skin.
The site was covered with gauze and Flexifix, which was held
in place with surgical tape. This was removed 24 h post
immunization, and site was swabbed with sterile PBS to
remove any remaining vaccine. Immunizations were
administered three times at weekly intervals, and an
immunization booster was given 2 weeks following the third
immunization.
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Live infection control (LIC)
Mice (n=5 per group) were given 2.5 mg
medroxyprogesterone acetate subcutaneously and infected
intravaginally 7 days later with 5x104 IFU of live C. muridarum
as described. Mice were re-infected 42 days after the primary
infection.
Sample collection
Vaginal washes were collected by flushing the vaginal vault
with 40 µL sterile PBS. This was repeated daily for 4 days,
concluding on day of euthanasia. Vaginal washes collected
across the timepoints were combined, so that each animal was
sampled across an entire estrus cycle. Mice were euthanized
on day 35 through intraperitoneal injection with 1 mL/2 kg
sodium pentobarbitone. Blood was collected via intracardiac
puncture and then centrifuged at 12 000 x g for 45 minutes to
obtain serum. Both serum and vaginal washes were stored at
-20 °C. Spleens were surgically removed and pooled for each
group.
ELISA analysis
ELISA 96-well plates (Interpath, Heidelberg West, VIC,
Australia) were coated with 2 µg MBP-MOMP/well in borate
buffer solution (BBS), then incubated at 4 °C overnight. Plates
were washed 3x with PBS containing 0.5% Tween 20 (PBS-T)
and blocked with 5% fetal bovine serum in PBS-T at 37 °C for 2
h. ELISAs were performed with serum and vaginal wash
samples as previously described [34,41]. MBP-MOMP specific
IgG and IgA were detected with 1/1000 HRP- conjugated goat
anti-mouse IgG and goat anti-mouse IgA respectively
(Southern Biotech, InVitro Technologies, VIC, Australia).
Samples collected from naïve mice were used as negative
controls to determine the end point titre (EPT) threshold, which
is the mean absorbance of the negative control + 2 standard
deviations. EPT of the test samples were calculated as the
inverse of the sample dilution at which absorbance values were
equivalent to the EPT threshold.
In vitro neutralization of C. muridarum infection
Sera collected from mice post immunization and 35 days
post-infection (LIC) was diluted 1/10, 1/20, 1/40, and 1/80 in
media in 96 well round bottom microplates (Nunc). Each well
was incubated with 1.25 x 104 IFU of C. muridarum for 1 h at
37 °C. Following incubation, the contents were transferred from
each well to a corresponding well in 96 well flat bottom
microplate (Nunc, Thermo Scientific, Australia)) containing 80%
confluent McCoy cell monolayers. The plates were incubated at
37 °C and infection proceeded for 24 h as described above.
Following fixation, wells were blocked with 5% fetal bovine
serum in PBS-T at 37 °C for 2 h. Wells were incubated with
1/500 sheep anti-C. muridarum MOMP for 1 h at 37 °C, then
with 1/2000 donkey anti-sheep IgG Alexa Fluor 488 (Invitrogen)
and 1/40 000 DAPI nucleic acid stain (Invitrogen) to visualise
inclusions and cells respectively. These were photographed
using fluorescence microscopy on x4 magnification and
percent infectivity was determined using MetaMorph counting
software (MDS Analytical Technologies). Neutralisation was
calculated by comparing the change in percent infectivity of a
sample well, to a control well containing no sample.
Splenocyte proliferation
Spleens were processed as previously described [41].
Splenocytes were added in quadruplets to 96-well plates at
5x105 cells/well, then stimulated with 10 µg MBP-MOMP/well
and incubated at 37 °C for 3 days. Half the media from each
well was then removed and stored at -80 °C for cytokine
assessment; [methyl-3H] Thymidine (MP Biomedicals,
Australasia, Seven Hills, NSW, Australia) was then added to
the remaining media at 0.5 µCi/well. The plates were incubated
at 37 °C overnight, then harvested onto a filtermat using a
Brandel 96-well plate harvester. Filtermats were wetted with
Betaplate Scint (PerkinElmer) and the incorporated
radioactivity was measured using a 1450 MicroBeta Liquid
Scintillation and Luminescence Counter plate reader
(PerkinElmer).
Cytokine assessment
Supernatants from stimulated splenocytes that were
collected for cytokine assessment were centrifuged at 500 x g
for 10 mins to remove debris. Quadruplet supernatants were
pooled and analysed as duplicates on Bio-Plex Pro mouse
cytokine immunoassay for IL-2, IL-4, IL-5, IL-10, IL-12(p70),
GM-CSF, IFNγ and TNFα (Bio-Rad, Regents Park, NSW,
Australia), according to the manufacturers instructions.
Statistics
All statistical analyses were performed using GraphPad
Prism v.5. Statistical significance was determined using
unpaired, two-tailed Student’s t-test with 95% confidence
interval (C.I.). Statistical significance was accepted at p <0.05.
Results
Characterization of the course of a chlamydial infection
in wild type (WT) versus IL-17 knockout mice
Both WT and IL-17-/- mice were infected intravaginally with
C. muridarum. Swabs were collected every 3 days for 21 days
for evaluation of chlamydial shedding and infectious burden. As
shown in Figure 1A, the absence of IL-17 had little effect on
bacterial clearance from the lower genital tract between days 3
to 12 although vaginal shedding was significantly reduced at
day 6 p.i. Furthermore, C. muridarum ompA transcripts were
2-5-fold higher in oviducts of WT mice compared to IL-17-/-
mice at day 6 p.i. (data not shown). However, the chlamydial
burden in the lower genital tract was significantly higher in WT
mice compared to the IL-17-/- mice during the later stage of
infection at days 15 and 18 p.i. (p<0.05). At day 21, all WT
mice were still shedding C. muridarum into the vaginal vault,
whereas 33% of IL-17-/- mice had cleared the infection (data
not shown). Calculation of the area under the curve (AUC)
allows a combined comparison of both the magnitude and
duration of infection. AUC analysis (Figure 1B) confirms the
reduced infection in IL-17-/- mice. These data show that in the
absence of IL-17, mice clear a vaginal C. muridarum infection
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PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e76664
more quickly than their WT counterparts and the overall burden
of Chlamydia is reduced.
Infection induced chronic disease in the upper genital
tract
C. muridarum infection of WT mice caused the development
of significant hydrosalpinx compared to non-infected WT
controls. However, infected IL-17-/- mice did not develop
significant hydrosalpinx and levels of inflammation were no
different to that seen in non-infected WT or IL-17-/- mice
(Figure 2). The lack of gross disease pathology in IL-17-/- mice
was supported by the histological analysis of innate immune
cell infiltration into the oviducts. At day 6 p.i., the oviducts of
WT mice contained significant numbers of Gr-1+ neutrophils
(Figure 3A) whilst the oviducts of IL-17-/- mice contained very
few infiltrating neutrophils (Figure 3B). Image analysis of Gr-1+
cell numbers in the oviducts at day 6 p.i. confirmed that
significantly more neutrophils were recruited into the oviducts
of WT mice compared to IL-17-/- mice (Figure 3C). A similar
observation was seen with oviduct sections stained with F4/80,
revealing infiltrating macrophages. Oviduct macrophage
numbers in WT mice (Figure 4A) were greatly increased at day
6 p.i. compared to oviducts of IL-17-/- mice (Figure 4B) and the
increased macrophage numbers in WT mice were significantly
higher (Figure 4C) at this time.
Infection-induced MMP2 and MMP9 expression in
reproductive tract tissues
Because IL-17 has been associated with the activation of
MMPs in other inflammatory conditions, we investigated the
expression of MMP2 and MMP9 in reproductive tract tissues of
WT and IL-17-/- mice following C. muridarum infection.
Oviducts and uterine horns were collected at day 7, which
represents the peak of infection following C. muridarum
challenge. Pro-MMP9 levels were significantly increased in
oviducts from WT mice compared to IL-17-/- mice at 7 days p.i.
as determined by both ELISA (p<0.0005, indicating zymogen
MMP-9) and gelatin zymography (p<0.05, indicating active
MMP-9, Figure 5) and remained increased at day 14 p.i.,
although this was only significant as determined by
zymography (p<0.05). Late in the infection (day 21), the trend
was reversed and higher levels of pro-MMP9 were found in the
uterine horns of IL-17-/- mice compared to WT mice (p<0.05,
Figure 5). Pro-MMP2 was higher in oviducts of uninfected WT
mice compared to IL-17-/- mice (p<0.0005), however there was
no difference between levels in infected WT and IL-17-/- mice
at any time p.i. Higher levels of pro-MMP2 were found in
uterine horns of IL-17-/- mice compared to WT at 21 days p.i.
(p<0.05) and active MMP2 was also increased in IL-17-/- mice
at 14 days p.i. (p<0.05).
Figure 1.  Clearance of vaginal C. muridarum infection in BALB/c and IL-17-/- mice.  Vaginal swabs were collected every 3
days following challenge of progesterone primed mice with 5 x 104 C. muridarum. The number of IFU per swab was determined by
culture on McCoy cells. The numbers of IFU per swab (A) and the area under the clearance curves (B) are presented. (*) or dotted
bar represents p<0.05 significance.
doi: 10.1371/journal.pone.0076664.g001
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Vaccine-induced serum and vaginal MOMP antibodies
are increased in IL-17-/- mice
We have previously shown that IN immunization protects
against C. muridarum genital tract infection [31,32].
Furthermore, Zygmunt et al. [35] have shown that IN
immunization preferentially induces Th17 cell responses,
regardless of the adjuvant used. It was therefore of interest to
determine if IN immunization of IL-17-/- mice could protect
against infection and oviduct inflammation. Serum and vaginal
washes were collected following IN immunization with MOMP
and CT/CpG and MOMP-specific IgG and IgA levels
determined by ELISA (Figure 6). Anti-MOMP antibody
responses elicited by a natural infection were also determined.
MOMP-specific IgG and IgA in serum was significantly higher
in IL-17-/- mice compared to WT mice (p<0.05) following IN
immunization and anti-MOMP IgG levels elicited by a natural
infection were also significantly higher in the IL-17-/- animals
(p<0.05, Figure 6). The IgG subclass of the vaccine-induced
serum IgG response was also significantly different in IL-17-/-
mice. IN immunization of WT mice resulted in an IgG response
dominated by the IgG1 subclass (IgG1: IgG2a ratio 26.2:1)
whereas in the serum of immunized IL-17-/- mice the IgG1
response was less dominant (IgG1: IgG2a ratio 3.6:1). Serum
IgA levels following natural infection were equivalent between
strains whereas IN immunization elicited higher serum IgA
levels in IL-17-/- mice compared to WT (p< 0.05, Figure 6).
MOMP-specific IgG levels were significantly higher in vaginal
washes of IL-17-/- mice compared to WT (p<0.05) following
Figure 2.  Infection-induced occlusion of
oviducts.  Hydrosalpinx was measured at 35 days post
infection following challenge of WT BALB/c and IL-17-/- mice
with 5 x 104 C. muridarum. Dotted bar represents p<0.05
significance.
doi: 10.1371/journal.pone.0076664.g002
Figure 3.  Neutrophil infiltration of oviducts following C.
muridarum infection.  Oviducts were collected from WT
BALB/c mice (A), IL-17-/- mice (B) 6 days post infection and
stained for Ly-6G/Ly-6C as described in materials and
methods. Staining of oviduct tissues was quantitated by image
analysis (C) as described in methods. Scale bar = 100 µM.
Dotted bar represents p<0.05 significance.
doi: 10.1371/journal.pone.0076664.g003
Figure 4.  Macrophage infiltration of oviducts following C.
muridarum infection.  Oviducts were collected from WT
BALB/c mice (A), IL-17-/- mice (B) 6 days post infection and
stained for F4/80 as described in materials and methods.
Staining of oviduct tissues was quantitated by image analysis
(C) as described in methods. Scale bar = 200 µM. Dotted bar
represents p<0.05 significance.
doi: 10.1371/journal.pone.0076664.g004
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Figure 5.  Expression of matrix metalloproteinase MMP9 and MMP2 in oviducts and uterine horns of wild type BALB/c and
IL-17-/- mice 7 days post infection with C. muridarum.  MMP expression was determined by both ELISA and gelatin zymography
as described in materials and methods. Dotted bar represents p<0.05 significance.
doi: 10.1371/journal.pone.0076664.g005
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immunization but levels elicited by natural infection were
equivalent (Figure 6). Significantly higher levels of both
vaccine-induced and infection-induced IgA in VL were found in
IL-17-/- mice compared to WT controls (p<0.05).
In vitro neutralization of C. muridarum by serum from
WT and IL-17-/- mice
Despite the increased levels of serum antibodies in IL-17-/-
mice following IN immunization the neutralizing activity of
serum from IL-17-/- mice was not significantly greater than that
of serum from similarly immunized WT mice (Table 1). At a
1:10 dilution, serum from knockout mice neutralized infection
by 64 + 8% whilst serum from WT mice reduced infection by 59
+ 6%. Although the Chlamydia-neutralizing capacity of sera
from WT and IL-17-/- mice following IN immunization was
equivalent this was not the case for sera collected following
resolution of a natural infection (LIC). Sera from IL-17-/- mice,
collected 35 days post-infection had significantly greater
neutralizing activity than sera collected from WT mice. WT
serum, at a 1:20 dilution failed to neutralize in vitro C.
muridarum infection whilst sera from IL-17-/- mice still
neutralized infection by ~50% at this dilution.
MOMP-induced in vitro splenocyte proliferation was
significantly higher in IN immunized WT mice compared to
IL-17-/- mice (p<0.05, Figure 7A). Interestingly, proliferation of
splenocytes isolated from animals that had recovered from a
natural infection, although lower overall than proliferation levels
Figure 6.  MOMP-specific IgG and IgA in serum and vaginal
wash fluids following intranasal (IN) immunization and
resolution of a primary C. muridarum infection
(LIC).  MOMP-specific IgG and IgA antibodies were measured
by ELISA as described in materials and methods following
intranasal immunization or resolution of a primary vaginal
infection. Dotted bar represents p<0.05 significance.
doi: 10.1371/journal.pone.0076664.g006
in immunized animals, was higher in the IL-17-/- mice (p<0.05).
Supernatants from in vitro MOMP-stimulated spleen cells were
also assayed for cytokine levels by Bio-Plex assay (Figure 6B).
Of all the cytokines analysed, only IFNγ levels were different
between strains, with levels significantly higher in supernatants
from stimulated WT cells compared to IL-17-/- cells (p<0.05,
Figure 7B). In both WT and IL-17-/- mice that had recovered
from a natural infection (LIC), only low levels of TNFα and IL-12
were produced following in vitro re-stimulation of splenocytes
with MOMP. This suggests that during a natural infection
MOMP is a major target for humoral immunity (Figure 6) but is
not a dominant T cell antigen.
IN immunization reduces infection in WT but not IL-17-/-
mice
Following IN immunization, both WT and IL-17-/- mice were
challenged intravaginally with C. muridarum. WT and IL-17-/-
mice that had recovered from a previous C. muridarum
infection were also included as a prior infection protects against
subsequent challenge (Figure 8A, live infection control [LIC]).
The bacterial load in swabs collected every 3 days was
determined and graphed against time to generate clearance
curves (as for Figure 1A). These data are reported as area
under the curve (AUC) (Figure 8A), which reflects both the
magnitude of shedding at each time point and the duration of
infection. Consistent with the data in Figure 1, the AUC in naïve
animals was significantly reduced in IL-17-/- mice compared to
WT (p<0.05, Figure 8A), reflecting both a shorter duration of
infection and a lower burden. IN immunization of WT mice
significantly reduced the AUC as expected (p<0.05 compared
to non-immunized WT mice, Figure 8A), however immunization
of IL-17-/- mice did not provide further protection as the AUC
for immunized IL-17-/- mice was not significantly different from
that of naïve knockout mice (Figure 8A). Interestingly, a prior
genital tract infection was able to protect both WT and IL-17-/-
mice against subsequent re-infection (Figure 8A, LIC) as
recoverable chlamydial IFU were reduced to below the limit of
detection in both strains. Protection against the development of
inflammatory pathology that can cause tubal occlusion has
been suggested to be an important requirement for a
chlamydial vaccine [46]. We therefore determined if vaccination
of WT and IL-17-/- mice prevented the development of oviduct
Table 1. Percentage neutralization of C. muridarum by
diluted serum collected from IN immunised and LIC wild
type and IL-17 - /- mice.
IN LIC
 WILD TYPE IL-17 -/-  WILD TYPE IL-17 -/-
1/10 58.7 ± 5.5 64.0 ± 8.4 1/10 47.5 ± 14.9 63.1 ± 10.7
1/20 26.7 ± 11.3 36.9 ± 10.5 1/20  -  50.4 ± 25.8
1/40 14.7 ± 8.9 5.7 ± 9.9 1/40  -   -  
1/80  -   -  1/80  -   -  
Values are mean +/- SD (n=5).Vaccine-induced T cell proliferation and cytokine
production in IL-17-/- and WT mice
doi: 10.1371/journal.pone.0076664.t001
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Figure 7.  MOMP-induced splenocyte proliferation and
cytokine secretion following intranasal (IN) immunization
or following resolution of infection (LIC).  Splenocytes were
stimulated in vitro with MOMP and proliferation (A) determined
by 3H-thymidine incorporation (CPM = counts per minute).
Cytokines secreted by MOMP-stimulated cells (B) were
measured by Bio-Plex assay as described in methods. Dotted
bar represents p<0.05 significance.
doi: 10.1371/journal.pone.0076664.g007
pathology (Figure 8B). Consistent with the data in Figure 2, C.
muridarum infection of naïve mice induced severe hydrosalpinx
in WT but not IL-17-/- mice. IN immunization of WT mice
protected against the development of hydrosalpinx (P<0.001
compared to non-immunized WT) but immunization of IL-17-/-
mice did not further reduce inflammation below that seen in
infected naïve knockout mice (p>0.05, Figure 8B). IN
immunization is known to preferentially elicit Th17 responses
[35], therefore, we also investigated if TC immunization could
induce protection against hydrosalpinx in IL-17-/- mice as we
had shown previously that TC immunization protected BALB/c
mice against genital tract chlamydial infection [41,47]. TC
immunization of WT mice with MOMP and CT/CpG reduced
the bacterial burden (AUC) in WT mice by around 20% (data
not shown) and significantly reduced the severity of
hydrosalpinx compared to non-immunized WT mice (p<0.0025,
Figure 8B). However, TCI of IL-17-/- mice did not reduce either
the infectious burden (AUC, data not shown) or the degree of
hydrosalpinx compared to naïve IL-17-/- mice (Figure 8B).
Discussion
In this study, we show that the magnitude and duration of a
vaginal C. muridarum infection in IL-17-/- mice is significantly
reduced compared to WT mice, with the reduction in infection
most evident late (days 12-21) in the course of infection (Figure
1A). Furthermore, following resolution of infection, IL-17-/- mice
fail to develop the severe hydrosalpinx that is seen in infected
WT mice at day 35 p.i. (Figure 2). All infected WT mice
developed severe unilateral, or in most cases bilateral
hydrosalpinx while oviducts isolated from IL-17-/- mice were no
different to those in uninfected WT or knockout controls.
Infiltration of neutrophils (Figure 3) and macrophages (Figure
4) into the oviducts at the peak of infection (day 6), was
significantly reduced in IL-17-/- mice. Pro MMP9 levels, as
measured by ELISA, were increased in oviducts of WT mice
compared to IL-17-/- mice at day 7 p.i. and remained elevated
at day 14 p.i. and zymography indicated comparatively
elevated gelatinase activity in WT mice (Figure 5). During the
later stages of infection (day 21) higher pro-MMP9 levels were
found in uterine horns of IL-17-/- mice. This delay in elaboration
of pro MMP-9 and its related gelatinase activity is likely due to
the arrival of other inflammatory cells capable of producing
MMP-9, namely macrophages, at the later stage of infection.
However, a conclusive in situ study of cell types and MMP
expression would need to be conducted to be certain of this
assertion. Higher levels of pro-MMP2 and active MMP 2 were
seen in the uterine horns of IL-17-/- mice (Figure 5).
Interestingly, this enzyme is more constitutively expressed in
most tissues and is likely involved in tissue remodelling and
repair following an inflammatory insult. Taken together, these
results indicate that IL-17 either directly or indirectly influences
MMP production and activity during infection in this model.
Because MMPs have previously proven to be endline effectors
in this model, our data provide a link between a single signaling
molecule (IL-17) and an endline effector of tissue damage in
chlamydial infection. IL-17-induced increases in MMP activity
have been implicated in a number of other inflammatory
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conditions including experimental airways inflammation [25],
periodontal disease [48], arthritis [26,27], atherosclerosis [29]
and also cancer metastasis [28].
Both the enhanced clearance of infection and the reduced
oviduct pathology are likely due to the reduced inflammatory
cell influx observed in the IL-17-/- mice compared to WT mice.
Macrophages and PMN are major sources of IL-1β, a cytokine
that has been implicated in both pathology and clearance of
infection [49] [50]. Gr1+ granulocytes in upper genital tract
tissues are the major source of MMP9 [51], which was
increased in oviducts of WT mice early in infection. Due to the
reduced influx of inflammatory cells in IL-17-/- mice, decreased
production of these key inflammatory mediators is the most
likely explanation for the reduced hydrosalpinx. Infection of
neutrophils with C. muridarum delays neutrophil apoptotic
death [52], potentially providing a source of Chlamydia that
may reinfect genital epithelial cells. Apoptotic neutrophils
Figure 8.  The effect of immunization or a prior infection on
chlamydial clearance and development of
hydrosalpinx.  BALB/c or IL-17-/- mice were immunized by
either the intranasal (IN) or transcutaneous (TC) routes or
allowed to recover from a C. muridarum infection (LIC). Vaginal
swabs were collected every 3 days following challenge. The
number of IFU per swab was determined by culture on McCoy
cells and plotted against time. From these plots, the area under
the curve was calculated (A). Hydrosalpinx was measured at
day 35 post-infection (B) as described in materials and
methods. Dotted bar represents p<0.05 significance.
doi: 10.1371/journal.pone.0076664.g008
infected with C. pneumoniae are phagocytosed by
macrophages [53] [54], which become infected and can serve
as a Trojan horse to spread infection, although this has not
been demonstrated for C. muridraum. However, we and others
[55] have shown that macrophages can be directly infected
with C. muridarum providing a potential reservoir of Chlamydia
for reinfection. As observed in Figure 1A, there was a second
peak of infection at day 15, which could potentially be due to C.
muridarum released from neutrophils and/or macrophages,
which are recruited into the oviducts of WT but not IL-17-/-
mice.
Following IN immunization, MOMP-specific IgG and IgA titers
were higher in serum and vaginal washes of IL-17-/- mice
(Figure 6). IgG1/IgG2a ratios were also different in serum of
WT and IL-17-/- mice following IN immunization, showing a
Th2-dominant response in WT mice, consistent with the Th2
bias of BALB/c mice, but a more balanced Th1/2 response in the
knockout mice. Th17 cells have been shown to increase B cell
proliferation in vitro, to induce isotype switching to IgG1, IgG2a,
IgG2b and IgG3 both in vitro and in vivo following
subcutaneous immunization of mice with Freund’s incomplete
adjuvant and to enhance germinal centre formation [56].
However, following IN immunization with MOMP plus CT/CpG
adjuvants there was no difference in the ability of serum from
either group to neutralize C. muridarum infection in vitro (Table
1). Natural genital infection also induced higher serum IgG and
vaginal IgA levels in IL-17-/- mice compared to WT mice and
importantly, sera from IL-17-/- mice showed significantly
greater neutralizing activity than WT sera (Table 1). This higher
neutralizing activity likely contributed to the enhanced
resolution of infection in IL-17-/- mice during the late stages of
infection. The higher levels of IgA in both serum and vaginal
washes of IL-17-/- mice is potentially at odds with the findings
of Hirota et al. [57], who found that serum and fecal IgA elicited
by oral immunization with cholera toxin was dependent on
Th17 cells. Because the development of intestinal Th17 cells is
dependent on the presence of commensal microbiota [58], the
IL-17 dependence of IgA production may be unique to the
intestine and not a feature of IgA production in the genital tract,
where the microbial burden is greatly reduced, or IgA
responses elicited by nasal immunization, as demonstrated in
our study.
Following IN immunization, splenic T cell proliferation after in
vitro culture with MOMP was significantly greater in WT mice
(Figure 7A). Stimulated WT cells also secreted significantly
higher levels of IFNγ while levels of the other cytokines
assayed were equivalent (Figure 7B). As expected, IN
immunization of WT mice significantly reduced both infection
(Figure 8A) and inflammatory disease (Figure 8B), however
immunization was ineffective in further reducing either infection
(Figure 8A) or disease (Figure 8B) in IL-17-deficient mice, most
likely due to decreased IFNγ production and the ability to
mount a protective Th1 response. Interestingly however, a prior
C. muridarum infection was able to reduce the magnitude and
duration of infection in both WT and IL-17-/- mice (Figure 8A).
Collectively our data suggest that IL-17 plays a major role in
the development of pathology/disease following chlamydial
infection and furthermore, delays infection resolution in BALB/c
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mice. The cytokine data (Figure 7B) suggest that in the
absence of IL-17 the knockout mice were unable to mount an
effective Th1 response, as evidenced by the greatly reduced
secretion of IFNγ. IL-17 has been shown to be essential for the
generation of Th1 responses in murine models of colitis [59]
and generation of anti-mycobacterial immunity elicited by
immunization with BCG [60]. The mechanisms involve either (i)
IL-23/IL-17 dependent suppression of IL-10 [60], facilitating the
development of Th1 cells (ii) co-expression of both IL-17 and
IFNγ or (iii) the direct conversion of Th17 cells into Th1 cells,
indicating the great plasticity of the Th17 cell lineage [61] [62].
Indeed, recent studies have demonstrated a dependence on
early IL-17 production, possibly produced by γδ T cells, for
generation of effective Th1 immunity against pulmonary
Mycobacterial infection elicited by BCG [63] [60], suggesting
that IL-17 may be essential for generation of Th1 immunity
against intracellular pathogens.
Our findings are in contrast to those of Scurlock et al. [22],
who found no difference between the rate of resolution of
genital infection and pathology development in WT and IL-17
receptor (IL-17ra-/-) knockout mice. It is possible that deletion
of the IL-17ra does not totally abolish IL-17A/F-mediated
signalling. Both IL-17A and IL-17F signal through a receptor
complex of IL-17ra and IL-17rc (reviewed in 64), two of the five
receptors that comprise the IL-17R family. Whilst the current
view is that IL-17rc cannot induce signalling in the absence of
IL-17ra [64] there are known to be many splice isoforms of
IL-17rc and the tissue expression pattern of IL-17rc is different
to that of IL-17ra, being low in hematopoietic cells but higher in
non-immune cells [65]. Thus it may be possible for some splice
variants of IL-17rc alone or complexed with other IL-17R family
members to mediate some IL-17 signalling. If this were shown
to be the case in the reproductive tract this could provide an
explanation for the different outcomes of C. muridarum
infection in IL-17ra-/- [22] and IL-17-/- mice.
Scurlock et al. [22] also found increased cervical
macrophages in IL-17ra-/- mice compared to WT mice
following infection and suggested that this may be a
compensatory mechanism for reduced Th1 immunity. However,
in our study, macrophage numbers in oviducts of IL-17-/- mice
were reduced compared to WT (Figure 4C) but infection
resolved more quickly and pathology was greatly reduced.
IL-17 has recently been shown to favour the activation of pro-
inflammatory M1 macrophages over anti-inflammatory M2
macrophages [66]. If the residual macrophages in IL-17-/-
mouse tissues were M2 type macrophages this could also have
contributed to the reduced hydrosalpinx seen in knockout mice.
Preliminary PCR analysis of markers associated with M1
versus M2 development demonstrated increased mRNA levels
of M2-associated markers CD206 and FIZZ1 [67] [68] in
oviducts of IL-17-/- mice at day 6 (data not shown) while iNOS
and CD86 transcripts were higher in WT mice compared to
IL-17-/- mice, findings consistent with an M2 bias early in
infection of the IL-17 knockout mice. IL-17 has been shown to
synergize with IFNγ to upregulate iNOS and NO production in
both epithelial cells and macrophages to inhibit C. muridarum
growth, which could explain the higher iNOS expression in WT
oviducts. It will be important to isolate pure macrophage
populations from the reproductive tracts of both strains to
confirm this potential bias. Another potential explanation is that
the IL-17ra-/- mice were on a C57 background while the
IL-17-/- mice in our study were on a BALB/c background.
Differences in the course and outcomes of C. muridarum
genital infections, including the time to clearance, the
development of hydrosalpinx and infertility and the Th1/Th2
bias [69] have been observed in different strains of mice
[70,71]. Similar strain-dependent differences in weight loss,
neutrophil influx and chlamydial tissue burden in lungs are also
seen following C. muridarum pulmonary infection of mice [72].
IL-17 has indeed been implicated in protection against
chlamydial pulmonary infections [49] as well as genital tract
infection. Antibody-mediated neutralization of IL-17 during a C.
muridarum pulmonary infection resulted in greater weight loss,
higher organism growth and more severe lung pathology
compared to mice that received isotype-control antibody [73],
suggesting that IL-17 is important for resolution of pulmonary
chlamydial infection. This study also showed that neutralization
of IL-17 reduced the capacity of dendritic cells to elicit
protective Th1 immunity, and that these DC were more likely to
induce Th2 immunity [73]. IL-17 also synergizes with IFNγ to
increase iNOS and NO production by macrophages to inhibit in
vitro growth of C. muridarum [55] and in vivo neutralization of
IL-17 reduced iNOS expression in mouse lung, which resulted
in greater C. muridarum burden. Together, these studies
suggest that IL-17, together with IFNγ, is important for
macrophage activation, most likely M1 macrophages, to clear
pulmonary chlamydial infection. Collectively, these studies
suggest that the mechanisms of clearance of C. muridarum
differ between the lung, where IL-17 is important, and the
genital tract, where both infection and pathology are less
severe in the absence of IL-17.
In summary, our data show that IL-17 has contrasting effects
on the course of a natural C. muridarum infection and the
development of vaccine-induced immunity. In the absence of
IL-17 the course of a natural infection is significantly attenuated
and hydrosalpinx fails to develop. This is likely due to a
combination of the greatly reduced influx of inflammatory cells
in IL-17-/- mice together with the development of higher levels
of Chlamydia-neutralizing antibody. However, in the absence of
IL-17, immunization protocols that protect WT mice against
infection and inflammation are ineffective due to the greatly
reduced production of IFNγ and protective Th1 immunity.
These results highlight the diverse roles of IL-17 and the
plasticity of Th17 cells and suggest that understanding the pro-
inflammatory versus protective mechanisms elicited by this
cytokine will be key to the development of a successful
chlamydial vaccine. We would strongly suggest however, that
potential human vaccines must not enhance the recruitment of
inflammatory cells into oviducts/fallopian tubes which would
likely result in increased inflammatory damage and blockage
leading to infertility, the most costly outcome of chlamydial
infection. Thus the aim of a vaccine should be to prevent
ascending infection, which may not require induction of
sterilizing immunity [46].
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